Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [31] Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
    Au, Daniel
    Lee, Eugene K.
    Popoola, Taiye O.
    Parker, William P.
    Saint Onge, Jarron M.
    Ellis, Shellie D.
    INTERNATIONAL BRAZ J UROL, 2021, 47 (04): : 803 - 818
  • [32] Treatment delays for muscle-invasive bladder cancer
    Masic, Selma
    Smaldone, Marc C.
    CANCER, 2019, 125 (12) : 1973 - 1975
  • [33] Landmarks in the treatment of muscle-invasive bladder cancer
    Niyati Lobo
    Chloe Mount
    Kawa Omar
    Rajesh Nair
    Ramesh Thurairaja
    Muhammad Shamim Khan
    Nature Reviews Urology, 2017, 14 : 565 - 574
  • [34] Landmarks in the treatment of muscle-invasive bladder cancer
    Lobo, Niyati
    Mount, Chloe
    Omar, Kawa
    Nair, Rajesh
    Thurairaja, Ramesh
    Khan, Muhammad Shamim
    NATURE REVIEWS UROLOGY, 2017, 14 (09) : 565 - 574
  • [35] Impact of rural residence on the presentation, management and survival of patients with non-metastatic muscle-invasive bladder carcinoma
    Dursun, Furkan
    Elshabrawy, Ahmed
    Wang, Hanzhang
    Kaushik, Dharam
    Liss, Michael A.
    Svatek, Robert S.
    Gore, John L.
    Mansour, Ahmed M.
    INVESTIGATIVE AND CLINICAL UROLOGY, 2023, 64 (06) : 561 - 571
  • [36] Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer
    Crijnen, Jasper
    De Reijke, Theo M.
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (02) : 135 - 147
  • [37] Commentary: underutilization of curative-intent therapy for patients with muscle-invasive bladder cancer in Sweden mimics the United States
    Clinton, Timothy N.
    Wiseman, Michal
    Walasek, Aleksandra
    Pietzak, Eugene
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S542 - S545
  • [38] Health-related quality of life after curative treatment for muscle-invasive bladder cancer
    Grobet-Jeandin, Elisabeth
    Pinar, Ugo
    Parra, Jerome
    Roupret, Morgan
    Seisen, Thomas
    NATURE REVIEWS UROLOGY, 2023, 20 (05) : 279 - 293
  • [39] ETIOLOGY OF TREATMENT DELAYS IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    El-Arabi, Ahmad
    Sherman, Garth
    Holzbeierlein, Jeffrey
    Lee, Eugene
    Wulff-Burchfield, Elizabeth
    JOURNAL OF UROLOGY, 2019, 201 (04): : E1025 - E1026
  • [40] Etiology of Treatment Delays in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
    El-Arabi, Ahmad M.
    Alam, Syed M.
    Sherman, Garth
    Parker, William P.
    Thompson, Jeffrey
    Holzbeierlein, Jeffrey M.
    Lee, Eugene K.
    Wulff-Burchfield, Elizabeth M.
    BLADDER CANCER, 2020, 6 (04) : 435 - 444